Results 11 to 20 of about 28,818 (194)
Frontiers in Cell and Developmental Biology, 2022 Mammalian target of rapamycin (mTOR) inhibitors (sirolimus or everolimus) have been demonstrated effective in reducing the size of tuberous sclerosis complex (TSC)-associated retinal astrocytic hamartoma (RAH) in short term.
Chen-Xi Zhang +6 more
doaj +1 more source
Orphanet Journal of Rare Diseases, 2023 Objectives Patients with vascular anomalies (VAs) who receive oral sirolimus may be at high risk of infectious complications. Antibiotic prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMZ) has been advocated.
Tong Qiu +13 more
doaj +1 more source
Pharmaceutics, 2021 Sirolimus is widely used in transplantation, where its therapeutic drug monitoring (TDM) is well established. Evidence of a crucial role for sirolimus in the PI3K/AkT/mTor pathway has stimulated interest in its involvement in neoplasia, either as ...
Amelia-Naomi Sabo +5 more
doaj +1 more source
Sirolimus in the treatment of kaposiform lymphangiomatosis [PDF]
Orphanet Journal of Rare Diseases, 2021 AbstractBackgroundKaposiform lymphangiomatosis (KLA), which is a new subtype of generalized lymphatic anomaly, is a rare disease with a poor prognosis. Currently, there is no standard treatment due to the poor understanding of KLA. Sirolimus, which is an inhibitor of mammalian target of rapamycin, has been shown to have promising potential in the ...
Jiangyuan Zhou +3 more
openaire +4 more sources
Quantification of sirolimus by liquid chromatography-tandem mass spectrometry using on-line solid-phase extraction [PDF]
, 2002 Quantification of the new immunosuppressant sirolimus (syn. rapamycin; Rapamune((R))) in whole blood by chromatography is essential for its clinical use since no immunoassay is available although monitoring is mandatory.
Fleischer, Claudia +5 more
core +1 more source
Sirolimus-Induced Angioedema [PDF]
American Journal of Transplantation, 2004 Sirolimus (SRL) is a macrolide immunosuppressant that has gained widespread use in organ transplantation. Its full spectrum of side-effects is yet to be defined. We describe herein three cases of SRL-induced angioedema (AE) in African-American (AA) primary renal allograft recipients who received SRL in combination with mycophenolate mofetil and ...
Hani M. Wadei +8 more
openaire +3 more sources
Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel [PDF]
, 2020 No biomarker panel is established for prediction of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD), a major complication of allogeneic stem cell transplantation (alloSCT).
Blau, Igor W. +10 more
core +3 more sources
Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease [PDF]
, 2018 Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the development of kidney cysts leading to kidney failure in adulthood. Inhibition of mammalian target of rapamycin (mTOR) slows polycystic kidney disease (PKD) progression in ...
Arcaro, Alexandre +10 more
core +2 more sources
Pharmacokinetic analysis after implantation of everolimus-eluting self-expanding stents in the peripheral vasculature [PDF]
, 2012 Background: A novel self-expanding drug-eluting stent was designed to release everolimus 225 mu g/cm(2) to prevent restenosis following peripheral arterial intervention.
Hausegger, Klaus A +7 more
core +2 more sources
CAQ Corner: Basic concepts of transplant immunology
, 2022 Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley +1 more source